JAK-STAT signaling emerges as a direct tissue target in Sjögren’s disease
Human salivary gland tissue has now been tied to a measurable immune circuit that is already familiar from other autoimmune diseases: the JAK-STAT pathway. In Sjögren’s disease, that pathway was activated in minor salivary glands, where interferon-driven immune activity tracked with disease-relevant features including focus scores and anti-SSA positivity. The finding matters because it moves the biology beyond broad inflammatory labeling and into a signaling route that can be pharmacologically interrupted.
The tissue data were not limited to one assay or one compartment. Bulk RNA sequencing, single-cell RNA sequencing, immunofluorescence microscopy, and flow cytometry converged on the same conclusion: interferon-stimulated genes were upregulated, and JAK-STAT signaling was active in affected glands. Peripheral blood mononuclear cells showed a similar inflammatory pattern, extending the signal beyond the target organ and into systemic immune cells that may contribute to fatigue, constitutional symptoms, and other extraglandular disease features.
A single signaling axis was operating in multiple compartments.
Interferon-stimulated genes rose with disease burden
The most clinically relevant biology was not simply that interferon signaling was present, but that its transcriptional footprint linked to measurable disease variables. Elevated ISG expression in minor salivary glands associated with focus scores and anti-SSA positivity, two markers that have long helped define immune activity in Sjögren’s disease. In practical terms, the pathway was not an incidental molecular curiosity; it was aligned with recognized indicators of immune-mediated gland injury.
Single-cell profiling added another layer. Upregulation of JAK-STAT genes and ISGs varied by cell type, showing that the inflammatory program was not uniform across the gland. Different populations within the tissue appear to be responding in distinct ways, which is biologically important because glandular dysfunction in Sjögren’s disease is not produced by a single cell type acting alone. Epithelial cells, infiltrating immune cells, and local stromal elements likely participate in a feed-forward loop in which interferon exposure maintains immune activation and tissue dysfunction.
Peripheral blood findings echoed the tissue signal. Monocytes showed markedly increased ISG expression, supporting the idea that systemic innate immune activation accompanies the local glandular process. That pattern fits the broader clinical picture of Sjögren’s disease, where patients often experience symptoms that extend well beyond dryness alone.
Ex vivo JAK inhibition corrected aberrant immune activation
The most persuasive part of the study was functional. Ex vivo assays on patient-derived cells showed that basal phosphorylated STAT levels were elevated in Sjögren’s disease minor salivary glands and peripheral blood mononuclear cells, then corrected with JAK inhibitor exposure. In other words, the pathway was not only present but drug-responsive.
Primary salivary gland epithelial cells from affected patients also behaved abnormally at baseline. They expressed higher levels of ISGs and mounted exaggerated responses to IFN-β. JAK inhibition normalized those responses without cytotoxicity, an important safety signal in a tissue model where epithelial survival is central to preserving gland function. Since epithelial cells help maintain secretory architecture and local immune balance, dampening their interferon hypersensitivity may be one route to protecting glandular integrity rather than merely suppressing downstream inflammation.
The bedside relevance is straightforward. If a therapy can reduce interferon-driven immune activation inside the gland itself, it may have a better chance of improving the underlying disease process than treatments that only blunt symptoms or dampen inflammation nonselectively. The biology also offers a plausible path for benefit across both glandular and extraglandular manifestations, because PBMC abnormalities and tissue-level changes moved in parallel.
Why this mechanism matters for a disease defined by immune overactivation
Sjögren’s disease has long been recognized as an autoimmune disorder in which salivary and lacrimal gland dysfunction reflects sustained immune assault and epithelial injury. Interferons sit near the center of that biology. They amplify antigen presentation, shape monocyte behavior, and reinforce inflammatory gene programs through JAK-STAT signaling. When that axis remains active, it can sustain a local immune environment that becomes increasingly self-perpetuating.
The study’s tissue-level correction of pSTAT activity and ISG expression suggests that JAK inhibition interrupts that loop at a biologically relevant point. This is especially important in Sjögren’s disease because the disease has often been difficult to treat with approaches that do not directly address the molecular drivers inside the affected glands. A therapy that normalizes signaling in epithelial and immune compartments offers a more targeted rationale than nonspecific immunosuppression.
The work also helps explain why disease heterogeneity has complicated prior therapeutic efforts. If JAK-STAT activation is cell type-dependent, then the same medication may produce different effects across glandular epithelium, monocytes, and other immune subsets. Recognizing that heterogeneity could improve patient selection in future trials and sharpen biomarker strategies.
A phase Ib/IIa tofacitinib trial has already begun
These data have already moved the field into interventional testing. A phase Ib/IIa randomized controlled trial of tofacitinib in Sjögren’s disease has been initiated on the strength of the tissue and ex vivo findings.
The move to trial testing is logical, but the translational question remains whether tissue normalization will translate into clinically meaningful improvement in dryness, fatigue, pain, and systemic symptoms. The current study establishes a biological rationale, not a clinical outcome dataset. It also does not identify which patients are most likely to benefit, how durable pathway suppression may be, or whether specific tissue signatures will predict response.
What it does show is that the immune abnormality in Sjögren’s disease is not abstract. It is measurable in glandular tissue, reproducible in blood, and reversible in experimental systems with JAK inhibition. For a disease in which symptom burden often outpaces available targeted therapies, that level of mechanistic coherence is a substantial step toward rational treatment design.